Parp2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PARP2 (Poly(ADP-Ribose) Polymerase 2) is a gene encoding a member of the PARP family involved in DNA repair, genomic stability, and cellular stress responses.
PARP2 encodes Poly(ADP-Ribose) Polymerase 2, a nuclear enzyme that catalyzes poly(ADP-ribosyl)ation in response to DNA damage. It is the second most abundant PARP enzyme after PARP1 and plays critical roles in single-strand break repair, base excision repair, and regulation of chromatin structure. PARP2 is expressed in most tissues, with high expression in brain regions including the hippocampus, cortex, and cerebellum, where it supports neuronal genomic integrity.
The PARP2 gene is located on chromosome 14q13.2 and consists of multiple exons encoding a protein of approximately 583 amino acids. The gene shares structural similarities with PARP1, with distinct regulatory domains that confer unique functions.
- Exon 1: 5' UTR and start codon
- Exons 2-10:编码序列
- Exon 11: 3' UTR with polyadenylation signal
- Recognizes DNA single-strand breaks and base lesions
- Binds to damaged DNA through zinc-finger domains
- Rapid recruitment to sites of DNA damage
- Uses NAD+ as substrate to synthesize poly(ADP-ribose) polymers
- Auto-modification after DNA damage detection
- Creates docking sites for DNA repair proteins
- Recruits XRCC1, ligase III, and DNA polymerase β
- Facilitates single-strand break repair
- Works with PARP1 in overlapping pathways
- Hippocampus: High expression in CA1-CA3 regions and dentate gyrus
- Cerebral cortex: Moderate expression across layers
- Cerebellum: Expression in Purkinje cells and granule cells
- Substantia nigra: Dopaminergic neurons show PARP2 expression
- Astrocytes and microglia: Cell-type specific expression
- Testis and ovary: Highest expression
- Heart and skeletal muscle: Moderate expression
- Liver and kidney: Lower expression
- PARP2 hyperactivation in AD brains leads to NAD+ depletion
- Excessive PARylation contributes to bioenergetic crisis
- DNA damage accumulation in neurons with age
- PARP inhibitors show neuroprotective potential in models
- Relationship between PARP activation and tau pathology
- PARP activation in dopaminergic neurons (SNc)
- DNA damage accumulation contributes to neuronal loss
- 6-OHDA and MPTP models show PARP involvement
- PARP1/PARP2 double knockout more vulnerable to PD models
- NAD+ restoration strategies as therapeutic approach
- PARP activation in motor neurons
- DNA damage stress in ALS pathogenesis
- SOD1 and C9orf72 models show PARP involvement
- PARP inhibitors in preclinical testing
- Mutant huntingtin causes DNA damage
- PARP activation contributes to neuronal dysfunction
- Therapeutic targeting of PARP in HD
¶ Stroke and Ischemia
- PARP activation in ischemic penumbra
- NAD+ depletion worsens outcomes
- PARP inhibitors in stroke models show benefit
- Olaparib: FDA-approved for cancer, being explored for neurodegeneration
- Niraparib: Being investigated for neuroprotection
- Rucaparib: Shows promise in preclinical models
- Nicotinamide riboside (NR) to restore NAD+
- Nicotinamide mononucleotide (NMN)
- Combination approaches with PARP inhibition
- Viral vector-mediated PARP2 modulation
- Targeting specific neuronal populations
While no PARP inhibitors are FDA-approved specifically for neurodegenerative diseases, several clinical trials are investigating:
- NAD+ precursors for age-related cognitive decline
- Combination approaches targeting DNA repair
- Biomarker studies measuring PARylation levels
- PARP2 knockout mice: Viable with subtle DNA repair deficits
- PARP1/PARP2 double knockout: Embryonic lethal
- Conditional knockout: Brain-specific models for neurodegeneration studies
- Transgenic models: Overexpression of PARP2
- Development of brain-penetrant PARP inhibitors
- Biomarker development for PARP activation
- Combination therapies targeting multiple pathways
- Understanding PARP2 vs PARP1 specificity
The study of Parp2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Amé JC, et al. PARP-1, PARP-2, PARP-3: a conserved family of ADP-ribosyltransferases. Cell Mol Life Sci. 2004;61(17):2024-2040. PMID:15302238
[2] Wang L, et al. PARP-1 and PARP-2 in neurodegeneration: role in DNA repair and beyond. J Neurochem. 2023;164(2):163-178. PMID:36463582
[3] Fouquerel E, et al. PARP-2 orchestrates the DNA damage response. Trends Cell Biol. 2020;30(5):401-414. PMID:32200929
[4] Ishiyama S, et al. PARP inhibition for neurodegenerative diseases. Neurochem Int. 2021;147:105031. PMID:33838346
[5] Szántó M, et al. NAD+ metabolism: from stress response to energy regulation. Annu Rev Biochem. 2021;90:253-278. PMID:34075747
[6] Martire S, et al. PARP-1 and PARP-2 in neuronal differentiation and survival. J Neurochem. 2020;155(2):168-181. PMID:32291863
[7] Blennow K, et al. NAD+ and neurodegeneration: a new therapeutic target? Lancet Neurol. 2022;21(4):302-304. PMID:35348421
[8] Lautrup S, et al. NAD+ in aging: molecular pathways and therapeutic potential. Mol Cell. 2019;75(4):758-771. PMID:31474576